ORDER NOW

Print 
$2,750.00 

Single-site or operational unit license 
$3,500.00 

Country or Global license 
Contact David Cunningham, 
Account Manager, 
781-972-5472 
cunningham@
healthtech.com

Length 
198 pages 

Date published 
October 2006 

Additional info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

Potential Breakthroughs in Neurotherapeutics: Alzheimer's Disease, Parkinson's Disease, Depression, Bipolar Disorder, and Schizophrenia

Ken Rubenstein, Ph.D. 

New Page 1

Table 4.1.Potential Alzheimer’s Disease-Modifying or Preventing Compounds in R&D

Table 4.2.Potential Ion Channel Modulating Compounds in Development for Alzheimer’s Disease

Table 4.3. Compounds in Development for Alzheimer’s Disease, Miscellaneous Mechanisms

Table 4.4. Potential Targets and Target Classes for Alzheimer’s Disease

Table 4.5. Compounds in Development for Parkinson’s Disease

Table 4.6. Potential Targets and Target Classes for Parkinson’s Disease

Table 4.7. Compounds in Development for Unipolar Depression

Table 4.8. Potential Targets and Target Classes for Unipolar Depression

Table 4.9. Compounds in Development for Bipolar Disorder

Table 4.10. Potential Targets and Target Classes for Bipolar Disorder

Table 4.11. Antipsychotic Compounds in Development

Table 4.12. Genes That Have Been Linked to Susceptibility for Schizophrenia

Table 4.13. Potential Targets and Target Classes for Schizophrenia

 


About Insight Pharma Reports

How to Order

Journalist Inquiries

Corporate Librarians and Information Services Inquiries

The Insight Pharma Reports Advisory Board

Contact Insight Pharma Reports

 

"CHI's Insight
 Pharma Reports are
 a cost-effective and reliable source
 of information about the markets
 we serve. The cost
 for us to conduct
 this kind of business
 research on our
 own would be
 prohibitive. CHI's
 Insight Pharma
 Reports allow us to
 keep on top of
 developments in
 this rapidly moving
 field." 

--Donald N. Halbert, Ph.D., EVP of R&D, Iconix Biosciences

 

A division of 
Cambridge 
Healthtech Institute


CHI's Insight Pharma Reports, a division of Cambridge Healthtech Institute | 250 First Avenue | Needham, MA 02494
For more information, email Rose LaRaia at rlaraia@healthtech.com or call 781-972-5444